SCHEMBL7249223

SCHEMBL7249223

OCc1c[nH]c(-c2ccc(SC(F)(F)F)c(Cl)c2)n1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
NOTUM Q6P988 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7157340 0.80 NOTUM (0.48) NOTUM
SCHEMBL7159598 0.72 KMO (0.45)
SCHEMBL23778736 0.71 NOTUM (0.45) NOTUM
SCHEMBL7158317 0.70 KIF11 (0.54)
SCHEMBL7248333 0.70 GFER (0.46) NOTUM
SCHEMBL7161302 0.69 KMO (0.43)
SCHEMBL26500690 0.68 SMN1; SMN2 (0.39)
SCHEMBL23778668 0.68 ALDH1A1 (0.42) NOTUM
SCHEMBL4880561 0.67 NR1H2 (0.42)
SCHEMBL10558227 0.66 ALDH1A1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610723-B2 Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration HOFFMANN-LA ROCHE INC. 2003-08-26 US disclosed
US-20020151715-A1 Imidazole derivatives EVOTEC INTERNATIONAL GMBH (DE) 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151715-A1 Imidazole derivatives GRIN2B, GRIN1, GRIN2A CYP3A4 4242/4885CYP2C9 4835/4885NOTUM 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.